The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Targeting NFE2L2/KEAP1 mutations in advanced NSCLC with the TORC1/2 inhibitor TAK-228.
 
Paul K. Paik
Honoraria - Abbvie; Celgene; Lilly; Takeda
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Celgene; Lilly
Research Funding - Celgene; EMD Serono
Travel, Accommodations, Expenses - EMD Serono
Other Relationship - Takeda
 
Linda Su Hyun Ahn
No Relationships to Disclose
 
Michelle S. Ginsberg
No Relationships to Disclose
 
Andrew J. Plodkowski
No Relationships to Disclose
 
Rachel Kim
No Relationships to Disclose
 
L. Austin Doyle
Patents, Royalties, Other Intellectual Property - I receive royalties for a patent related to cloning and characterizing the ABCG2 transporter. This patent is administered through the University of Maryland School of Medicine. The patent has nothing to do with my current work or any work in ASCO abstrac
 
Charles M. Rudin
Consulting or Advisory Role - Abbvie; Ascentage Pharma; AstraZeneca; Bicycle Therapeutics; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Daiichi Sankyo; Elucida Oncology; Genentech/Roche; Harpoon Therapeutics; Ipsen; Loxo; PharmaMar; PharmaMar; Seagen
Research Funding - Abbvie/Stemcentrx (Inst); Daiichi Sankyo (Inst); Merck (Inst); Viralytics (Inst)